Tongguo Shi | Cancer | Best Researcher Award

Posted on by sciencefather

Dr. Tongguo Shi | Cancer | Best Researcher Award

Tongguo Shi is an Associate Researcher at the First Affiliated Hospital of Soochow University, specializing in cancer immunology and molecular medicine. He earned his PhD from Nanjing University in 2016 and has since focused on tumor immune evasion, immune checkpoint regulation, and colorectal cancer research. His work has been published in leading journals such as Cancer Immunology, Immunotherapy and Cell Death & Disease, with multiple studies highlighting novel therapeutic targets. With expertise in molecular biology and immunological assays, he is dedicated to advancing cancer immunotherapy and precision medicine.

Dr. Tongguo Shi | The First Affiliated Hospital of Soochow University | China

Profile

SCOPUS ID

ORCID ID

🎓Education

  • Tongguo Shi earned his PhD from Nanjing University in 2016, following his undergraduate studies at Liyi University, where he obtained a BA in 2010. His academic journey has equipped him with a strong foundation in medical and biological research, particularly in immunology and oncology.

👨‍🏫Experience

  • Currently serving as an Associate Researcher at the First Affiliated Hospital of Soochow University, Tongguo Shi has been contributing to medical research since December 2021. Prior to this role, he worked as a Research Associate at the same institution from 2017 to 2021, where he gained extensive experience in cancer immunology and molecular medicine. He also served as a Research Associate at the Center of Systems Medicine, Chinese Academy of Medical Sciences, from 2016 to 2017, further strengthening his expertise in cellular and molecular research.

🏆Awards and Recognitions

  • Throughout his career, Tongguo Shi has established himself as a leading researcher, contributing significantly to cancer immunotherapy and colorectal cancer studies. His role as a corresponding author in multiple high-impact journal publications highlights his expertise and recognition in the scientific community. His work on immunological mechanisms in cancer and inflammatory diseases has been widely cited, demonstrating the impact of his research.

💡Skills and Certifications

  • Tongguo Shi specializes in immuno-oncology, with a focus on tumor microenvironments, immune evasion mechanisms, and cancer immunotherapy. His research has explored the role of immune checkpoints such as B7-H3 and Tim-3 in colorectal and gastric cancers, as well as the impact of microRNAs on immune regulation in inflammatory diseases. His skills include molecular biology techniques, immunological assays, cancer cell signaling analysis, and translational research aimed at developing novel therapeutic strategies.

🔬 Research Focus

  • His research has led to groundbreaking findings on the interactions between immune cells and cancer cells, with a particular emphasis on T cell-mediated immune responses. He has published extensively in prestigious journals such as Cancer Immunology, Immunotherapy, Cell Death & Disease, Mucosal Immunology, and Gut, further advancing the understanding of cancer immunology and potential therapeutic interventions.

🌎Conclusion

  • Dr. Tongguo Shi exemplifies scientific excellence and collaborative leadership in cancer research. His work has significantly advanced the understanding of tumor immunology, cancer metabolism, and immunotherapy through high-impact interdisciplinary collaborations. His strong publication record, mentorship, and institutional partnerships highlight his commitment to groundbreaking discoveries that benefit both scientific progress and patient outcomes.

📖Publications

  • Elevated SPARC Disrupts the Intestinal Barrier Integrity in Crohn’s Disease by Interacting with OTUD4 and Activating the MYD88/NF‐κB Pathway
    Authors: J. Wang, Jiayu; Y. He, Yuxin; X. Zhu, Xingchao; J. Zhu, Jinghan; Z. Deng, Zilin; H. Zhang, Huan; Y. Chen, Yanjun; G. Zhang, Guangbo; T. Shi, Tongguo; W. Chen, Weichang
    Journal: Advanced Science, 2025

  • FASN Promotes Lipid Metabolism and Progression in Colorectal Cancer via the SP1/PLA2G4B Axis
    Authors: X. Liu, Xin; J. Lu, Jiachun; X. Ni, Xiangyu; Y. He, Yuxin; J. Wang, Jiayu; Z. Deng, Zilin; G. Zhang, Guangbo; T. Shi, Tongguo; W. Chen, Weichang
    Journal: Cell Death Discovery, 2025

  • Exploring the Link Between Noncoding RNAs and Glycolysis in Colorectal Cancer
    Authors: L. Xu, Liang; Y. Shen, Yu; C. Zhang, Chuanqiang; T. Shi, Tongguo; X. Sheng, Xuejuan
    Journal: Journal of Cellular and Molecular Medicine, 2025

  • The m6A Revolution: Transforming Tumor Immunity and Enhancing Immunotherapy Outcomes
    Authors: T. Shi, Tongguo; H. Zhang, Huan; Y. Chen, Yueqiu
    Journal: Cell & Bioscience, 2025

  • Exosome-Derived Proteins in Gastric Cancer Progression, Drug Resistance, and Immune Response
    Authors: J. Wang, Jiayu; H. Zhang, Huan; J. Li, Juntao; X. Ni, Xiangyu; W. Yan, Wenying; Y. Chen, Yueqiu; T. Shi, Tongguo
    Journal: Cellular & Molecular Biology Letters, 2024

Lina Wang | Oncology | Best Researcher Award

Posted on by sciencefather

Assoc Prof Dr.Lina Wang | Oncology | Best Researcher Award

Grant Funding:
  •  Dr. Wang has been the recipient of competitive research funding from the National Natural Science Foundation of China, which further underscores her research capabilities and the recognition of her work at the national level.
Assoc Prof Dr. Lina Wang, Affiliated Hospital of Jining Medical University, China

Profile

Scopus

OrcID

🏛️Early Academic Pursuits

  • Lina Wang completed her Bachelor’s degree at Taishan Medical University (2004-2010), followed by a Master’s degree from Peking Union Medical College (2010-2013). She further pursued her Ph.D. in Medicine at Shanghai Jiao Tong University School of Medicine (2013-2017). With an unrelenting drive for excellence, she completed a postdoctoral fellowship at the University of Maryland School of Medicine (2018-2020), where she deepened her understanding of oncological research and built a strong foundation for her future studies.

👨‍🔬 PROFESSIONAL ENDEAVORS

  • Since July 2017, Lina Wang has been serving as an Associate Professor at the Affiliated Hospital of Jining Medical University. Her professional journey has been marked by significant strides in cancer research, particularly focusing on lung cancer, esophageal cancer, and leukemia. She is committed to advancing cancer diagnosis, treatment, and prognosis through rigorous scientific investigation. Her postdoctoral research at the University of Maryland significantly enhanced her expertise in molecular oncology.

🏆 CONTRIBUTIONS AND RESEARCH FOCUS

  • Lina Wang’s research has brought significant advancements in the understanding of cancer pathogenesis, particularly in lung and esophageal cancers. Her work in developing efficient prognostic models based on cuproptosis and disulfidptosis has established her as a leader in the field of cancer biomarkers. She has extensively explored the molecular mechanisms underlying tumor progression and has validated several diagnostic and prognostic biomarkers for lung adenocarcinoma. Notably, her research on the TGF-β1/SH2B3 axis has provided new insights into the regulation of anoikis resistance and epithelial-mesenchymal transition (EMT) in lung cancer cells. Additionally, her earlier studies demonstrated that the deletion of Stk40 impairs definitive erythropoiesis in mouse fetal livers, contributing to the broader understanding of developmental biology.

📊 IMPACT AND INFLUENCE

  • Lina Wang’s groundbreaking research has not only advanced scientific knowledge but also holds potential to transform clinical practices in cancer diagnosis and treatment. By identifying tumor-associated diagnostic and prognostic markers, her work offers tangible benefits to clinical patients, improving the precision of medical interventions. Her research on the molecular mechanisms driving cancer progression contributes to the development of targeted therapies that can effectively treat aggressive cancers such as lung adenocarcinoma.

💰GRANTS AND FUNDING

  • Lina Wang’s research efforts have been recognized by the National Natural Science Foundation of China, which awarded her a grant (grant no. 81800182) for her project from 2019 to 2021. This funding has enabled her to push the boundaries of cancer research, supporting her work on diagnostic and prognostic markers, as well as molecular mechanisms in oncology.

🏅ACADEMIC CITES

  • Lina Wang’s publications on topics such as cuproptosis and cancer prognosis have been widely cited in scientific literature, reflecting the relevance and influence of her work in the academic community. Her research has contributed to the establishment of new prognostic models, and her findings have been cited in numerous oncology-focused journals, further solidifying her reputation as a key contributor in cancer research.

🚀LEGACY AND FUTURE CONTRIBUTIONS

  • As Lina Wang continues her academic journey, her future contributions promise to further enhance the understanding of cancer mechanisms and improve treatment strategies. With a focus on the identification of novel biomarkers and therapeutic targets, her work is expected to have a lasting impact on the fields of oncology and personalized medicine. Her ongoing research efforts are set to leave a lasting legacy in the medical community, inspiring future generations of researchers.

📄Publications

  •  Construction of lncRNA Prognostic Model Related to Disulfidptosis in Lung Adenocarcinoma
    Authors: Zhang, L., Wang, S., Wang, L.
    Journal: Heliyon, 2024, 10(15), e35657
  •  Prognostic Value and Immunological Function of Cuproptosis-Related Genes in Lung Adenocarcinoma
    Authors: Zhang, L., Wang, S., Wang, L.
    Journal: Heliyon, 2024, 10(9), e30446
  • LncRNA CALML3-AS1 Modulated by m6A Modification Induces BTNL9 Methylation to Drive Non-Small-Cell Lung Cancer Progression
    Authors: Zhang, H., Wang, S.-Q., Zhu, J.-B., Duan, C.-J., Zhang, C.-F.
    Journal: Cancer Gene Therapy, 2023, 30(12), pp. 1649–1662
  •  Research Progress on Ferroptosis in Lung Cancer 
    Authors: Dong, Z., Wang, L., Zhang, L., Hu, R.
    Journal: Journal of Chinese Physician, 2023, 25(11), pp. 1754–1757
  •  Alterations of Gut Microbiota and Gut Metabolites in the Young-Adult Vitiligo Patients
    Authors: Wu, Q., Cheng, P., Shao, T., Yao, S., Lu, B.
    Journal: Journal of the European Academy of Dermatology and Venereology, 2023, 37(7), pp. e904–e907